---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-25-000107"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2025-09-02T23:59:59+00:00"
generated_at: "2026-05-17T08:59:34.158695+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Mineralys Therapeutics terminates ATM prospectus supplement, halts sales until new filing

## Summary
- Delivered written notice to BofA Securities and Evercore terminating prospectus supplement dated April 11, 2024.
- No further sales of common stock under the Sales Agreement will occur until a new prospectus supplement is filed.
- The underlying ATM Equity Offering Sales Agreement (March 21, 2024) remains in full force and effect.

## SEC filing metadata
- accession: 0001933414-25-000107
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2025-09-02T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341425000107/0001933414-25-000107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341425000107/mlys-20250902.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-25-000107
- JSON: https://secwatch.observer/filing/0001933414-25-000107.json
- Plain text: https://secwatch.observer/filing/0001933414-25-000107.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.